Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robotic surgery vs standard approaches: does the platform change cancer outcomes?

NCT ID NCT07821775

Knowledge-focused Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers at a large hospital in Seoul reviewed records from nearly 33,000 adults who had curative-intent surgery for one of seven cancers in the abdomen or pelvis: pancreatic, gastric, rectal, cervical, endometrial, kidney, or prostate. They grouped patients by whether they received open, laparoscopic (keyhole), or robotic surgery. The study asks whether robotic surgery is linked to better one-year cancer outcomes, such as freedom from recurrence or death, and whether any advantage holds after accounting for tumor stage, surgical complexity, and surgeon experience.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If robotic surgery shows better cancer outcomes for some of these seven cancers, it could help guide which surgical approach doctors recommend. It could also shape how surgeons are trained and how hospitals invest in robotic systems.
What could go wrong
This is a retrospective study, not a randomized trial, so differences between patient groups may reflect factors other than the surgical approach. The findings come from one hospital in South Korea and may not apply to other settings or surgeons.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

32,949 people

The number who actually took part.

Started

Jan 2012

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 years or older who underwent curative-intent abdominopelvic surgery for one of seven nonmetastatic malignant solid tumors (pancreatic, gastric, rectal, cervical, endometrial, kidney, or prostate cancer) at Asan Medical Center, a large tertiary referral center in Seoul, Republic of Korea, between January 1, 2012, and December 31, 2021.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Underwent curative-intent abdominopelvic surgery for a nonmetastatic malignant solid tumor of one of the following types: pancreatic, gastric, rectal, cervical, endometrial, kidney, or prostate cancer * Surgery performed between January 1, 2012, and December 31, 2021 * Available postoperative surveillance data Exclusion Criteria: * Presence of distant metastasis before surgery * Presentation with recurrent disease from previously treated cancer * Incomplete or missing key demographic, comorbidity, operative, or outcome data required for analysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer endometrial cancer endometrium neoplasm gastric cancer gastric neoplasm kidney cancer kidney neoplasm malignant pancreatic neoplasm pancreatic neoplasm prostate cancer prostate neoplasm rectal cancer rectal neoplasm Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial neoplasms Kidney neoplasms Pancreatic neoplasms Prostatic neoplasms Rectal neoplasms Stomach neoplasms Uterine cervical neoplasms

Contacts and locations

Locations

  • Asan Medical Center, University of Ulsan College of Medicine

    Seoul, Songpa-gu, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.